ARVO LIVE: Myopia progression with low-concentration atropine

Ophthalmology Times® talked with Mark Bullimore and discussed the control of myopia progression with low-concentration atropine from the Hong-Kong LAMP study at this year's ARVO meeting.

Video transcript

Editor’s note: Transcript lightly edited for clarity.

Mark Bullimore, PhD:

My name is Mark Bullimore. I'm an adjunct professor with the University of Houston College of Optometry, and I'm here at the ARVO meeting. I want to talk to you today about one of our presentations that concerns the control of myopia progression with low concentration atropine. Specifically, we looked at the data from the LAMP (Low-Concentration Atropine for Myopia Progression) study from Hong Kong, one of the most important studies of recent years. Now unfortunately, in the LAMP study, they only had control subjects on a placebo for the first year of a 3 year study. But what we were able to do is to take those 1 year data and predict what the control population would have done over the 3 years using a 15% slowing per year. And from that, we're able to estimate the free efficacy of the different concentrations of atropine. So I encourage you to look at the paper in the link below and thank you for your attention.

Link to paper.

Disclosure: Mark Bullimore is a consultant for Alcon Research, CooperVision, CorneaGen, EssilorLuxottica, Euclid Systems, Eyenovia, Genentech, Johnson & Johnson Vision, Lentechs, Novartis, Paragon Vision Sciences, and Vyluma.